Alzheimer’s Blood Marker Also Signals Heart & Kidney Disease Risk

A blood protein long recognized as an early signal of Alzheimer’s disease appears to have a broader role in systemic illness, potentially offering modern diagnostic avenues for conditions affecting the heart and kidneys. Researchers at the German Center for Neurodegenerative Diseases (DZNE) and the Hertie Institute for Clinical Brain Research (HIH) at the University of Tübingen have discovered elevated levels of phosphorylated tau protein (pTau) in individuals with transthyretin amyloidosis and immunoglobulin light-chain amyloidosis – two common forms of systemic amyloidosis. The findings, published in Nature Medicine, suggest pTau isn’t solely a marker for Alzheimer’s, but may indicate a more general cellular stress response to amyloid deposits throughout the body.

Amyloidosis refers to a group of diseases where abnormally folded proteins, called amyloids, build up in organs and tissues. While Alzheimer’s involves amyloid and tau deposits specifically in the brain, these other forms of amyloidosis affect organs like the heart and kidneys, with different proteins forming the deposits. Despite these differences, the Tübingen researchers observed a consistent elevation of pTau in the blood of affected individuals. This discovery, based on data from 280 older adults across Germany, Italy, and the Netherlands, could lead to less invasive and more accessible diagnostic tools.

Beyond the Brain: pTau as a Systemic Indicator

“Our results underscore that high pTau levels in blood are not specific to Alzheimer’s, but can as well occur in other amyloid diseases,” explains Mathias Jucker, professor and scientist at DZNE and HIH. The ease with which pTau can be measured in a blood sample offers a potential advantage over current diagnostic methods for systemic amyloidosis, which often rely on more complex and invasive procedures like tissue biopsies. The study, detailed in Nature Medicine, highlights the potential for pTau to facilitate earlier detection and aid in confirming or ruling out suspected cases of these conditions.

However, the findings also reinforce the need for careful interpretation of pTau levels in the context of Alzheimer’s disease diagnosis. As the article in Medical Xpress points out, pTau levels alone are not definitive and should be considered alongside other clinical data. This represents particularly crucial in individuals who haven’t yet developed cognitive impairments, where Alzheimer’s may be in its earliest stages.

Implications for Polyneuropathy Diagnosis

The implications of this research extend to the diagnosis of polyneuropathy (PNP), a condition characterized by tingling and numbness in the hands and feet. Systemic amyloidosis can be one underlying cause of PNP, but numerous other factors can also contribute. Jucker suggests that pTau measurements could help differentiate between PNP cases caused by amyloidosis and those stemming from other origins. This could streamline the diagnostic process and ensure patients receive the most appropriate treatment.

A Cellular Stress Response?

The question remains: why are pTau levels elevated in these diverse conditions? Jucker hypothesizes that pTau release is a cellular stress response triggered by amyloid deposits. This response, he suggests, may be a common reaction across various organs, not limited to the brain. Interestingly, temporary increases in pTau have been observed in hibernating animals, where they appear to play a protective role. This suggests that elevated pTau isn’t always detrimental and could, in some cases, represent a beneficial attempt by the body to cope with stress.

This finding aligns with growing understanding of tau’s role beyond neurodegeneration. While historically associated with Alzheimer’s disease and other tauopathies (diseases characterized by tau protein abnormalities), research is increasingly revealing tau’s involvement in various cellular processes, including stress response and inflammation. As detailed in a recent review in Molecular Neurobiology, the complexity of tau modifications across multiple sites is driving research into multi-site phosphorylation as a potentially more valuable diagnostic approach.

Diagnostic Accuracy and Future Directions

The study’s findings emphasize the importance of a comprehensive diagnostic approach when evaluating potential Alzheimer’s disease. Relying solely on pTau levels could lead to misdiagnosis, particularly in individuals without cognitive symptoms. Further research is needed to refine the use of pTau as a biomarker and to establish clear diagnostic thresholds for different conditions.

Looking ahead, researchers plan to investigate the specific mechanisms underlying pTau elevation in amyloidosis and other diseases. Understanding how amyloid deposits trigger the release of pTau could lead to the development of targeted therapies aimed at mitigating the cellular stress response and preventing organ damage. The team also intends to explore the potential of pTau as a monitoring tool to track disease progression and assess the effectiveness of treatments.

The discovery of pTau’s broader role underscores the interconnectedness of seemingly disparate diseases. It highlights the potential for shared biological pathways and the importance of a holistic approach to diagnosis and treatment. The ongoing research promises to refine our understanding of amyloidosis, Alzheimer’s disease, and the complex interplay between cellular stress and protein misfolding.

What’s next: Further studies are planned to validate these findings in larger and more diverse populations. Researchers will also focus on identifying the specific mechanisms linking amyloid deposits to pTau release, with the ultimate goal of developing more precise diagnostic tools and targeted therapies.